Titre : All-oral direct antiviral treatment for hepatitis C in a real-life cohort: The role of cirrhosis and comorbidities in treatment response
link : All-oral direct antiviral treatment for hepatitis C in a real-life cohort: The role of cirrhosis and comorbidities in treatment response
All-oral direct antiviral treatment for hepatitis C in a real-life cohort: The role of cirrhosis and comorbidities in treatment response
All-oral direct antiviral treatment for hepatitis C chronic infection in a real-life cohort: The role of cirrhosis and comorbidities in treatment response
Noelle Miotto , Leandro Cesar Mendes, Leticia Pisoni Zanaga,Maria Silvia Kroll Lazarini, Eduardo Sellan Lopes Goncales, Marcelo Nardi Pedro, Fernando Lopes Goncales Jr, Raquel Silveira Bello Stucchi, Aline Gonzalez Vigani
Full Article
Abstract
Background
Hepatitis C virus (HCV) infection is the major cause of end-stage liver disease (LD) worldwide. The aim of this study was to assess sustained virological response (SVR) rates in a real-world cohort of patients with HCV infection treated with interferon-free direct antiviral agents (DAA).
Patients and methods
All patients with genotypes 1, 2 or 3 HCV infection who started interferon-free treatment at a university hospital from December 2015 through July 2017 were included. The primary outcome was SVR at post-treatment week 12 by intention-to-treat (ITT) and modified ITT (mITT) analysis.
Results
Five hundred twenty seven patients were enrolled, 51.6% with cirrhosis. Most patients received sofosbuvir + daclatasvir + ribavirin (60.7%) and sofosbuvir + simeprevir (25.6%). Overall SVR rates were 90.5% for ITT and 96% for mITT. SVR rates were higher in non-cirrhotic (94.2% in ITT and 96.8% in mITT) versus cirrhotic patients (87.1% in ITT and 95.2% in mITT). In ITT and mITT assessments, SVR rates were higher in patients with Child-Pugh A (n = 222, 88.7% and 95.7%, respectively) versus Child-Pugh B or C (n = 40, 80% and 90%, respectively); SVR rates were higher in patients with genotype 1 (n = 405, 92.1% and 98.2%), followed by genotype 2 (n = 13, 84.6% and 92.7%) and genotype 3 (n = 109, 84.4% and 88.4%). Lower comorbidity index (p = 0.0014) and absence of cirrhosis (p = 0.0071) were associated with SVR. Among cirrhotic patients, lower Model for End-Stage Liver Disease (p = 0.0258), higher albumin (p = 0.0015), and higher glomerular filtration rate (p = 0.0366) were related to SVR. Twenty-two cirrhotic patients (8%) had clinical liver decompensation during treatment. Complications of advanced LD were responsible for discontinuation of treatment and death in 12 and 7 patients, respectively.
Conclusion
Treatment with all-oral DAA achieved high SVR rates, particularly in patients without cirrhosis and few comorbidities. Advanced LD is associated to poor outcome, such as treatment failure and death.
Continue reading: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0199941
Thus articles All-oral direct antiviral treatment for hepatitis C in a real-life cohort: The role of cirrhosis and comorbidities in treatment response
that is all articles All-oral direct antiviral treatment for hepatitis C in a real-life cohort: The role of cirrhosis and comorbidities in treatment response This time, hopefully can provide benefits to you all. Okay, see you in another article post.
You are now reading the article All-oral direct antiviral treatment for hepatitis C in a real-life cohort: The role of cirrhosis and comorbidities in treatment response the link address https://newsaninpiration.blogspot.com/2018/07/all-oral-direct-antiviral-treatment-for.html
0 Response to "All-oral direct antiviral treatment for hepatitis C in a real-life cohort: The role of cirrhosis and comorbidities in treatment response"
Post a Comment